Pediatric Disease Registry in Essential Thrombocythaemia (ET)

NCT ID: NCT01198717

Last Updated: 2021-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-28

Study Completion Date

2016-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the progression of ET in children (aged 6-17years inclusive) over a period of 5 years maximum. The study will also assess how children are diagnosed, treatment options for those children with symptoms and events related to their ET and the outcomes of those treatments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Essential Thrombocythemia (ET)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- 6 years or over and less than 18 years patient has ET according to the WHO criteria as guidance

Exclusion Criteria

* Interventional clinical study participation
Minimum Eligible Age

6 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shire

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Paediatric Clinic University Hospital Olomouc

Olomouc, , Czechia

Site Status

Clinic of Paediatric haematology and oncology University Hospital Motol

Prague, , Czechia

Site Status

Paediatric Oncology Unit, Hopital Cote De Nacre

Caen, , France

Site Status

Practicen Hospitalier , Institute d'Hematologie et Oncologie Pediatrique

Lyon, , France

Site Status

Centre Hospitalier Lyon Sud - service Hématologie

Pierre-Bénite, , France

Site Status

Hopitaux de Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Klinikum Chemnitz GmbH, Klinik für Kinder-und Jugendmedizin

Chemnitz, , Germany

Site Status

Zentrum für Kinder- und Jugendmedizin Klinik II / III

Frankfurt, , Germany

Site Status

"Agia Sophia" Children's Hospital

Athens, , Greece

Site Status

Dipartimento di Biomedicina dell'Eta Evolutiva. University of Bari

Bari, , Italy

Site Status

Servico de Oncoematologia Peditrica

Cagliari, , Italy

Site Status

UO Oncoematologia AOU Meyer

Florence, , Italy

Site Status

Pediatric Hamatology Unit. Department of Hematology and Oncology. G Gaslini Children's hospital. Largo

Genova, , Italy

Site Status

Chairmen of Pediatric Hamatooncology Outpatient Clinic. Hospital San Gerardo

Monza, , Italy

Site Status

Department of Oncology, Pausilipon Hospital, AORN Santobono

Napoli, , Italy

Site Status

Azienda Ospedaliera di Padova

Padua, , Italy

Site Status

Department of Cellular Biotechnologies and Hematology. Sapienza University

Rome, , Italy

Site Status

Ospedale Casa Sollievo della Sofferenza

San Giovanni, , Italy

Site Status

Hamatology Unit. Paediatric Department. University of Torino

Torino, , Italy

Site Status

Sección de Hematología Pediátrica. Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status

Hospital Universitario Mutua de Terrassa

Barcelona, , Spain

Site Status

Jefe de Servicio Oncología Y Hematología Pediátricas

Barcelona, , Spain

Site Status

Servicio de Hematología Clínica, Hospital Sant Joan de Déu Barcelona

Barcelona, , Spain

Site Status

Servicio de Transfusión, Hospital Universitario Niño Jesús

Madrid, , Spain

Site Status

Department Haematology, Hospital Ramon y Caja

Madrid, , Spain

Site Status

Hospital Universitario Virgen de la Arrixac

Murcia, , Spain

Site Status

Complexo Hospitalario Universitario, Santiago

Santiago de Compostela, , Spain

Site Status

Leitender Arzt, Pädiatrische Hämatologie/Onkologie Kinderspital

Lucerne, , Switzerland

Site Status

St James University Hospital

Leeds, , United Kingdom

Site Status

Royal Manchester Childrens Hospital,

Manchester, , United Kingdom

Site Status

Children's Clinic, Royal Berkshire Hospital

Reading, , United Kingdom

Site Status

Sheffield Childrens Hospital

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Czechia France Germany Greece Italy Spain Switzerland United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

https://clinicaltrials.takeda.com/study-detail/5f6b5fee4db2bf003ab47e5c

To obtain more information on the study, click here/on this link.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SPD422-404

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Eltrombopag in Chronic ITP
NCT04102033 UNKNOWN PHASE4